SCYX
Healthcare Drug Manufacturers - Specialty & GenericSCYNEXIS, Inc.
$5.12
-0.27 -4.94% today
Price History
Not enough data
Key Stats
Market Cap
50.94M
Avg Volume
270,714
EPS
-$0.89
52W High
$9.12
52W Low
$3.53
Div. Yield
0.0%
Analyst Ratings
Buy1
Str Buy
2
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-2.21
P/B Ratio
0.76
P/S Ratio
2.65
EV/Revenue
-0.06
Margins
Gross Margin 100.0%
Operating Margin (3308.5%)
Net Margin (53.3%)
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
(82.8%)
Return on Equity
(18.4%)
Return on Assets
(20.8%)
Liquidity & Leverage
Current Ratio
9.65
Quick Ratio
9.29
Debt / Equity
0.03
Total Cash
54.08M
Total Debt
1.95M
About
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
www.scynexis.com